Cohort profile: a multicentre prospective validation cohort of the Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study.
Cohort profile: a multicentre prospective validation cohort of the Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study.
复制标题
DOI：
10.1136/bmjopen-2020-037793
复制
发表时间：
2021-01-08
期刊：
影响因子：
2.9
通讯作者：
Li H
中科院分区：
文献类型：
--
作者：
Qiao L;Wang X;Deng G;Huang Y;Chen J;Meng Z;Zheng X;Shi Y;Qian Z;Liu F;Gao Y;Lu X;Liu J;Gu W;Zhang Y;Wang T;Wu D;Dong F;Sun X;Li H
急性慢性肝衰竭（ACLF）是一种短期死亡率高、机制不明确、诊断标准有争议的临床综合征。中国急性慢性肝衰竭（CATCH-LIFE）研究已经在中国进行，以填补这一空白。在第一阶段（CATCH-LIFE调查队列），2015-2016年，从中国12个不同省份的14个全国性肝脏中心连续招募了2600例患者，获得了一系列重要结果。为了验证初步结果，我们设计并进行了这个多中心前瞻性观察队列（CATCH-LIFE验证队列）。诊断为慢性肝病并因急性失代偿（AD）或急性肝损伤住院的患者被纳入研究，接受标准药物治疗。我们收集了参与者住院期间的人口统计资料、病史、实验室数据以及血液和尿液样本。从2018年9月到2019年3月，来自中国13个全国性肝脏中心的1370名年龄在15至79岁之间的患者（73.4%）被纳入研究。在这些患者中，952例（69.5%）患有慢性乙型肝炎，973例（71.1%）患有肝硬化，1083例（79.1%）在入院时合并AD。每个参与中心的入组患者的数量和比例以及患者的基线特征均被呈现。每位参与者总共需要12个月来完成随访。结果信息（生存、死亡或接受肝移植）的收集和数据清理将在2020年6月之前完成。CATCH-LIFE验证队列中的数据将用于比较来自CATCH-LIFE调查队列的新ACLF诊断标准与现有诊断标准。此外，未来的蛋白质组学和代谢组学分析将为ACLF的机制提供有价值的见解，这将促进特异性治疗的发展，从而降低患者的死亡率。NCT03641872。
Acute-on-chronic liver failure (ACLF) is a clinical syndrome with high short-term mortality, unclear mechanism and controversial diagnosis criteria. The Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study has been conducted in China to fill the gaps. In the first phase (the CATCH-LIFE investigation cohort), 2600 patients were continuously recruited from 14 national nationwide liver centres from 12 different provinces of China in 2015–2016, and a series of important results were obtained. To validate the preliminary results, we designed and conducted this multicentre prospective observational cohort (the CATCH-LIFE validation cohort). Patients diagnosed with chronic liver disease and hospitalised for acute decompensation (AD) or acute liver injure were enrolled, received standard medical therapy. We collected the participants’ demographics, medical history, laboratory data, and blood and urine samples during their hospitalisation. From September 2018 to March 2019, 1370 patients (73.4% men) aged from 15 to 79 years old were enrolled from 13 nationwide liver centres across China. Of these patients, 952 (69.5%) had chronic hepatitis B, 973 (71.1%) had cirrhosis and 1083 (79.1%) complicated with AD at admission. The numbers and proportions of enrolled patients from each participating centre and the patients’ baseline characteristics are presented. A total of 12 months is required for each participant to complete follow-up. Outcome information (survival, death or receiving liver transplantation) collection and data cleansing will be done before June 2020. The data in the CATCH-LIFE validation cohort will be used for comparison between the new ACLF diagnostic criteria derivated from the CATCH-LIFE investigation cohort with existing ones. Moreover, future proteomic and metabolic omics analyses will provide valuable insights into the mechanics of ACLF, which will promote the development of specific therapy that leads to decrease patients’ mortality. NCT03641872.
登录
查看更多内容
影响因子：
9.8
作者：
Blei, AT;Córdoba, J
通讯作者：
Córdoba, J
影响因子：
168.9
作者：
Tsochatzis, Emmanuel A.;Bosch, Jaime;Burroughs, Andrew K.
通讯作者：
Burroughs, Andrew K.
影响因子：
13.5
作者：
Bajaj, Jasmohan S.;O'Leary, Jacqueline G.;Reddy, K. Rajender;Wong, Florence;Biggins, Scott W.;Patton, Heather;Fallon, Michael B.;Garcia-Tsao, Guadalupe;Maliakkal, Benedict;Malik, Raza;Subramanian, Ram M.;Thacker, Leroy R.;Kamath, Patrick S.
通讯作者：
Kamath, Patrick S.
影响因子：
6.6
作者：
Sarin, Shiv Kumar;Kedarisetty, Chandan Kumar;Yokosuka, Osamu
通讯作者：
Yokosuka, Osamu
影响因子：
6.6
作者：
Sarin, Shiv Kumar;Kumar, Ashish;Yuen, Man-Fung
通讯作者：
Yuen, Man-Fung